View Post

Rare Patient Voice: Clinical Trial for Hodgkin’s Lymphoma Patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Details: Subjects enrolled would be treated every 3 weeks and Subjects may continue on treatment until disease progresses, unacceptable side effects, or study closure occurs Compensation Might be available Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need …

View Post

Rare Patient Voice: Hodgkin’s Lymphoma Patients, Ages 20-45

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 60 min Web-Assisted Phone Interview Compensation $90 via Gift Card  Please sign up at the link below for more information or to see if you qualify. https://rarepatientvoice.com/LetLifeHappen/ Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences?  We connect you with researchers who are developing products and services which can help …

View Post

Rare Patient Voice: Hodgkin’s Lymphoma Patients and Caregivers

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 30 min Online Survey Compensation $50 Please sign up at the link below for more information or to see if you qualify. https://rarepatientvoice.com/LetLifeHappen/ Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences?  We connect you with researchers who are developing products and services which can help you and others with …

View Post

3D Signatures announce the clinical trial component of its Hodgkin’s lymphoma validation program are underway

In In The News by Barbara Jacoby

3D Signatures is pleased to announce that the clinical trial component (the “Clinical Trial”) of its Hodgkin’s lymphoma (“HL”) test (“Telo-HL”) validation program is successfully underway. This process is referred to as Stage 3 of the validation program as set out in the company’s news release dated February 23, 2017. Assay development and assay validation, Stage 1 and Stage 2 …

View Post

Pharmacylic’s ‘miracle cure’: A cancer drug

In In The News by Barbara Jacoby

By: Jeremy Owens and Lisa M. Krieger From: mercurynews.com The small biotech company Pharmacyclics was on the ropes, teetering toward bankruptcy. Its one big product had flopped. Its top chemist, co-founders and entire board of directors resigned, frustrated and disappointed. Its new CEO knew almost nothing about biotech. And then the recession hit. All it had left was a single …